Strides said that Vecuronium is a nondepolarising neuromuscular blocking agent claimed to possess all of the characteristic pharmacological actions of this class of drugs (curariform). Vecuronium is about 1/3 more potent than Pancuronium, a muscle relaxant. The duration of neuromuscular blockade produced by Vecuronium is shorter than that of Pancuronium at initially equipotent doses.
Reportedly, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing Vecuronium doses.
Strides claimed that Vecuronium is expected to be offered as 10mg and 20mg, AP-rated, sterile nonpyrogenic freeze-dried product in packages of ten. The total 2009 US market for injectable Vecuronium is approximated $10m, according to IMS data.
Vecuronium is expected to be launched under the partnership between Strides and Akorn wherein Strides is developing and supplying 22 injectable products for the US market which is expected to be marketed by Akorn for Akorn-Strides, a joint venture between Strides and Akorn.